Methods for treating lung infections and inflammation
AssigneeBrigham Young University
InventorsPaul B. Savage, Carl A. Genberg, Michael D. Triplett
Life of this patent
Estimating the term…
Abstract
Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.
Claims52
A method of treating a patient having a lung infection and lung inflammation associated with the lung infection with a cationic steroidal antimicrobial (CSA) compound, comprising:
- administering via pulmonary administration by inhalation through the patient's mouth and into a lung of the patient having the lung infection a therapeutically effective amount of the CSA compound, which is a compound of Formula IB, or a pharmaceutically acceptable salt thereof, wherein the CSA compound provides antimicrobial activity and treats or reduces lung inflammation associated with the lung infection by modulating gene expression relating to inflammation, including causing negative fold regulation:
- wherein,
- R3, R7, and R12 are independently selected from the group consisting of aminoalkyloxy and aminoalkylcarboxy;
- and
- R18 is selected from the group consisting of alkylaminoalkyl;
- alkoxycarbonylalkyl;
- alkylcarbonyloxyalkyl;
- di(alkyl)aminoalkyl;
- alkylaminoalkyl;
- alkyoxycarbonylalkyl;
- alkylcarboxyalkyl;
- and hydroxyalkyl,
- with the proviso that the CSA compound is not CSA-13.
A method of treating a patient having a lung infection and reducing lung inflammation associated with the lung infection, with a cationic steroidal antimicrobial (CSA) compound, comprising:
- administering via pulmonary administration by inhalation into a lung of the patient having the lung infection a therapeutically effective amount of the CSA compound, which is a compound of Formula IB, or a pharmaceutically acceptable salt thereof, to treat lung inflammation associated with the lung infection, wherein the CSA compound modulates gene expression relating to inflammation, including causing negative fold regulation:
- wherein,
- R3, R7, and R12 are independently selected from the group consisting of aminoalkyloxy and aminoalkylcarboxy;
- and
- R18 is selected from the group consisting of alkylaminoalkyl;
- alkoxycarbonylalkyl;
- alkylcarbonyloxyalkyl;
- di(alkyl)aminoalkyl;
- alkylaminoalkyl;
- alkyoxycarbonylalkyl;
- alkylcarboxyalkyl;
- and hydroxyalkyl,
- with the proviso that the CSA compound is not CSA-13.
A method of treating a patient having a lung infection associated with cystic fibrosis, including reducing lung inflammation associated with cystic fibrosis, with a cationic steroidal antimicrobial (CSA) compound, comprising:
- administering via pulmonary administration by inhalation through the patient's mouth and into a lung of the patient having the lung infection associated with cystic fibrosis a therapeutically effective amount of the CSA compound, which is a compound of Formula IB, or a pharmaceutically acceptable salt thereof, wherein the CSA compound treats or reduces lung inflammation associated with the lung infection associated with cystic fibrosis by modulating gene expression relating to inflammation, including causing negative fold regulation:
- wherein,
- R3, R7, and R12 are independently selected from the group consisting of aminoalkyloxy and aminoalkylcarboxy;
- and
- R18 is selected from the group consisting of alkylaminoalkyl;
- alkoxycarbonylalkyl;
- alkylcarbonyloxyalkyl;
- di(alkyl)aminoalkyl;
- alkylaminoalkyl;
- alkyoxycarbonylalkyl;
- alkylcarboxyalkyl;
- and hydroxyalkyl,
- with the proviso that the CSA compound is not CSA-13.
Dependencies are inferred from the claim text.